The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 19, 2019

Filed:

Mar. 14, 2017
Applicant:

University-industry Foundation, Yonsei University, Seoul, KR;

Inventors:

Han Woong Lee, Seoul, KR;

Jung-Min Choi, Seoul, KR;

Byoung Chul Cho, Seoul, KR;

Yu-Ra Choi, Gangwon-do, KR;

Ji-Young Jang, Seoul, KR;

Hye Ryun Kim, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); A61K 31/47 (2006.01); A61K 31/277 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61K 31/444 (2006.01); A61K 31/4706 (2006.01); A61K 31/4709 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/277 (2013.01); A61K 31/444 (2013.01); A61K 31/47 (2013.01); A61K 31/4706 (2013.01); A61K 31/4709 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 38/1709 (2013.01); A61K 45/06 (2013.01); G01N 33/57496 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 33/57423 (2013.01);
Abstract

The present disclosure relates to a novel use of EI24, and provides a novel use of EI24 involved in the improvement of EGFR-TKI drug resistance by inhibiting IGF-1R signaling. According to the present disclosure, the presence or absence of resistance to anti-cancer drugs may be determined by detecting an expression level of EI24. In addition, resistance to anti-cancer drugs may be inhibited, delayed, or improved using EI24 or an activating agent thereof. Moreover, by regulating a pathway of EI24-mediated resistance to anti-cancer drugs, the efficacy of existing anti-cancer drugs may be enhanced, and resistance to anti-cancer drugs may be inhibited, delayed, or improved.


Find Patent Forward Citations

Loading…